Topics

ReViral Company Profile

07:16 EDT 18th September 2019 | BioPortfolio

http://www.reviral.co.uk


News Articles [7 Associated News Articles listed on BioPortfolio]

ReViral announces US$55 million series B fundraising to advance RSV clinical studies

London, UK, 1st August 2018 / Sciad Newswire / ReViral, an antiviral drug discovery and development company, focused on diseases caused by the Respiratory Syncytial Virus (RSV), today announced the ...

ReViral raises US$55m

ReViral appoints Dr Hetherington as Chief Medical Officer

The CMO appointment has been made as the company prepares its lead RSV candidate to enter phase II of clinical trials

ReViral Announces Grant of Key US Composition of Matter Patent for Their Respiratory Syncytial Virus Inhibitor Programme

Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended) ...

ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)

Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research (ICAR) ReViral Ltd.,...

ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as It Prepares Its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials

ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced the appointment of Seth Het...

ReViral Appoints Alex C. Sapir as Chief Executive Officer

Proven leader with extensive corporate strategy experience in the biotechnology sector Dr. Eddy Littler to remain as Chief Operating Officer ReViral Ltd., a cl...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

ReViral Ltd.

ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&...

ReViral

http://www.reviral.co.uk

More Information about "ReViral" on BioPortfolio

We have published hundreds of ReViral news stories on BioPortfolio along with dozens of ReViral Clinical Trials and PubMed Articles about ReViral for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ReViral Companies in our database. You can also find out about relevant ReViral Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record